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The crystal structure of ﬁbroblast growth
factor 18 (FGF18)
Dear Editor,
Fibroblast growth factors (FGFs) regulate a plethora of crit-
ical processes in development (Beenken and Mohammadi,
2009). These processes are mediated by signaling through
four FGF receptors (FGFR1–4), which are high-afﬁnity cell
surface receptor tyrosine kinases. Receptors 1–3 undergo
alternative splicing to generate b- and c-isoforms with altered
ligand speciﬁcities and afﬁnities. Ligand to receptor binding
is not unique and one receptor can be activated by several
FGFs. Heparan sulfate (HS) proteoglycan, a variably poly-
sulfated glycosaminoglycan related to heparin, is an
essential requirement for FGF signaling with FGFs varying in
their speciﬁcities for different HS sulfation patterns (Galla-
gher et al., 1992).
The 18 mammalian FGFs that are capable of signaling
through FGFRs share a conserved β-trefoil fold and are
grouped into 6 subfamilies (Itoh and Ornitz, 2004). FGF18
belongs to the paracrine-acting FGF8 subfamily, which
contains three members in humans: FGF8, FGF17, and
FGF18. The biological activities of FGF8 and FGF17 are
regulated by alternative splicing with four isoforms of FGF8
(a, b, e, and f) and two of FGF17. In contrast, FGF18 does
not undergo alternative splicing.
FGF18 has a number of functions in the developing and
adult organism including a key role in skeletal development
(Haque et al., 2007) and has undergone clinical trials for the
treatment of osteoarthritis (Merck KGaA). Pathologically,
FGF18 is implicated in colorectal (Shimokawa et al., 2003)
and ovarian cancer (Wei et al., 2013) and has been proposed
as an early marker and potential anticancer drug target.
In vivo, FGF18 is expressed as a precursor polypeptide of
207 residues with the initial 27 hydrophobic residues forming
a cleavable signal peptide. Residues 50–194 were expres-
sed in Escherichia coli and puriﬁed to homogeneity. The
interaction between FGF18 and heparin oligosaccharides
was examined using isothermal titration calorimetry (ITC),
Fig. S1A. FGF18 binds heparin oligosaccharides of 6 dp with
an afﬁnity of 2.2 ± 29.2 μmol/L. The interaction is enthalpy-
driven (ΔH = −8.6 kcal·mol−1) with a negative entropic con-
tribution (TΔS = −1.0 kcal·mol−1) giving an overall free
energy (ΔG) of −7.6 kcal·mol−1. A heparin oligosaccharide of
8 dp was sufﬁcient to dimerize FGF18 (Fig. S1B), as
observed for FGF1 (Brown et al., 2013).
FGF18 was incubated stoichiometrically with heparin (6
dp) and the complex isolated prior to crystallization in a
mother liquor of 0.1 mol/L MES pH 6.5, 0.2 mol/L ammonium
sulphate and 26% PEG 5000. FGF18 crystallized in the
primitive monoclinic spacegroup P21 with four FGF18 mol-
ecules in the asymmetric unit. Initial phases were provided
using molecular replacement with the FGF8b structure (PDB
ID: 2FDB) and reﬁned to 2.7 Å. Data collection and reﬁne-
ment statistics are shown in Table S1, with an example of the
electron density in Fig. S2.
The ﬁnal model consists of residues 50–179 and has a β-
trefoil core formed from ten anti-parallel β-strands arranged
in three groups of three or four strands connected by tight
turns and loops (Fig. 1A). Two strands from each group
come together to form a β-sheet barrel of six antiparallel β-
strands. There is a disulﬁde bridge between Cys109 and
Cys127 that joins the β6 strand with the β7–β8 loop, helping
to stabilize it. These cysteines are conserved throughout the
FGF8 subfamily with Cys127 conserved throughout the
entire FGF family. This disulﬁde bond restricts FGF18 to
exerting an extracellular function only, unlike other FGF
members that have intracellular roles. The four FGF18
molecules in the asymmetric unit have root mean-square
deviation (RMSD) of 0.30 Å2 (Cα atoms). Differences are
mainly at the crystal contact sites with greatest variation in
the β4–β5 loop, residues 90–96 (Fig. 1B), which in the FGF8
subfamily contains an extra serine residue that presumably
increases its ﬂexibility.
The members of the FGF8 subfamily differ in their spec-
iﬁcities and afﬁnities for FGFRs, although all lack afﬁnity for
FGFR b-isoforms. In comparative SPR assays, FGF18 has
been shown to have highest afﬁnity to either FGFR3c
(Hoshikawa et al., 2002) or FGFR1c (Olsen et al., 2006). The
latter study shows FGF18 has weaker afﬁnity for each
receptor than FGF8b. By comparing the structure of FGF18
with the binary complex of FGF8b-FGFR2c insights into their
different afﬁnities are possible. The FGF18-FGFR2c com-
plex was modelled by superposition of FGF18 onto FGF8b
(RMSD = 0.95 Å2) in the FGF8b-FGFR2c binary complex
(Olsen et al., 2006), Fig. S4A. The model demonstrates how
the extended and hydrophobic β4–β5 loop of FGF18 is
important for conferring FGFR binding speciﬁcity as it
engages the hydrophobic groove in the D3 domain of FGFR
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c-isoforms. In the FGFR b-isoform this region predominantly
contains hydrophilic residues that would repel FGF18 (Fig.
S4C and S4D).
Of the interface residues for which structural information
is present for both FGF8b and FGF18 only six vary,
Figs. 1C and S3. All of these residues are outside predicted
‘hot spots’ that are residues that make a dominant
contribution to the free energy of binding, typically
ΔΔG ≥ 2 kcal·mol−1, and that if mutated can have a sub-
stantial effect on the afﬁnity of the interaction. Many of
these mutations, for example Arg155 to Lys155, preserve
physicochemical properties. Cumulatively, these changes
may explain the different speciﬁcities/afﬁnities of FGF18
and FGF8b, however, it is likely that differences in the N-
and C-termini that are not resolved in the FGF18 crystal
structure, contribute substantially. The FGF18 structure is
missing the initial 23 residues of the mature polypeptide
and 28 residues from the C-terminus. In the crystal struc-
ture of FGF8b-FGFR2c, the FGF8b N-terminus is ordered
and tethered to the β4 strand and to the β4–β5 loop within
the β-trefoil core via numerous hydrophobic contacts and
hydrogen bonds. Residues, especially Phe32 and Val36,
from this structured N-terminus contact the hydrophobic
groove in the D3 domain of the receptor and help confer
speciﬁcity towards the c-isoforms. Phe32 has been shown
to be key in conferring the differing afﬁnities of FGF8a and
FGF8b for the FGFR (Olsen et al., 2006). There are 3
residues in this N-terminal section that differ between
FGF18 and FGF8b (Arg34 [Thr in FGF8b], Val37 [Leu] and
Lys49 [Arg]), Fig. S4B. The change from threonine in
FGF8b to arginine in FGF18, could reduce hydrophobic
packing with the hydrophobic groove of the D3 domain, and
therefore explain the weaker afﬁnity FGF18 has for each of
















Figure 1. The structure of FGF18. (A) Cartoon representation of the FGF18 crystal structure of protomer A. Sulfate ions are shown
in stick representation with sulfur in yellow and oxygen in red. The position of a sulfate found in another protomer in the asymmetric
unit is demarcated with an asterisk. (B) Structural heterogeneity in the β4–β5 loop from the four molecules in the asymmetric unit with
protomer A shown in dark blue. (C) Two views of the surface of FGF18. Residues equivalent to FGFR2c-binding residues in FGF8b
are shown in white with interface residues that differ in magenta. Asn139, a putative glycosylation site in the center of the FGFR
interface, is shown in yellow. A dashed orange line outlines the positions of ‘hot spot’ residues at the FGF8b-FGFR2c interface.
FGF18 polymorphisms that occur on the surface of the structure are shown in red. The position of Phe93 is indicated in each panel.
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HS is a necessary component of paracrine FGF signaling
complexes. The interaction with FGFs is dependent on for-
mation of suitable conformational and charge characteristics
that are complementary to the binding sites on the proteins
formed. However, these requirements can be satisﬁed by
multiple polysaccharide sequences (Beenken and Moham-
madi, 2009; Rudd et al., 2010). FGF18 has a lower strin-
gency for HS sulfation than other FGFs as it recognizes both
2-O-sulfated and 6-O-sulfated HS oligosaccharides, with a
preference for 2-O-sulfation (Ashikari-Hada et al., 2004).
Althoughelectrondensity for heparin hexasaccharide is not
present, 13 sulfate ionsare discernable in theasymmetric unit,
corresponding to 5 unique sulfate-binding locations (Fig. 1A).
The position of these sulfates, and the surface charge distri-
bution, offers clues to the mode of HS recognition by FGF18.
The position of sulfates within the FGF1 crystal structure were
ﬁrst used to correctly identify HS-binding residues (Blaber
et al., 1996). However, it should be noted that only highly co-
ordinated sulfate ions are likely to be ordered in the crystal
structure, and in the context of heparin, further sulfate-binding
positions are possible. A recent study has used a ‘protect and
label’ method to identify lysine residues that participate in
heparin-binding in FGF18 (Xu et al., 2012). From this, they
identiﬁed both a canonical and a secondary heparin-binding
site in FGF18. In our structure, sulfate ions are bound to the
canonical binding site, but not to the proposed secondary site.
A detailed viewof the atoms involved in contacting the sulfates
is shown in Fig. 2 along with a comparison of the positions of
sulfates from heparin in FGF1 and FGF2. Three of the ﬁve
sulfate ions are clustered in a location distinct from the hepa-
rin-binding sites of FGF1/2 (Fig. 2D–E), but occupy a contin-
uous stretch of basic residues that is, in part, formed by the
lysines identiﬁed as interacting with heparin by Xu et al.
(2012), and could represent an extension of the canonical site.
Whether these sites would be occupied in solution by a longer
stretch of HS or whether two HS molecules could bind simul-
taneously remains to be fully determined. However, the ITC
data (Fig. S1) suggests that FGF18cannot bind twomolecules
of heparin oligosaccharides of 6 dp or 8 dp simultaneously.
Alongside the lysine residues identiﬁed by Xu et al.
(2012), a number of arginine residues are involved in binding
the sulfate ions, more than identiﬁed in the FGF1/2-heparin
interfaces. The enthalpy of arginine residues for heparin
























Figure 2. Insights into theFGF18-HS interface fromboundsulfate ions. (A)Surfaceelectrostatic potentialswere calculated forFGF1
(top) and FGF18 (bottom). Red represents −5 e per Å and blue represents +5 e per Å. Heparin bound to FGF1 and sulfate ions bound to
FGF18 are shown in stick representation. Lysine residues fromFGF18 that contact heparin in solution (Xu et al., 2012) are shown; Lys155,
156,161,and164constitute thecanonicalHS-bindingsitewithanequivalent inFGF1,withLys113,115,119, and125unique toFGF18.The
heparin-binding interfaces of FGF1 (B), and FGF2 (C), compared to the location of sulfates bound to FGF18 (D and E). Sulfate ions or
sulfates fromheparin oligosaccharides are shownas large orange spheres. Interacting atomswith an inter-atomic distance equal to or less
than 3.6 Å are displayed as small spheres. Carbon atoms are colored yellow, oxygen atoms are colored red, and nitrogen atoms colored
blue. A dashed purple line shows the trajectory of the heparin sugar backbone. Key interacting residues are labelled.
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the guanidine groups producing stronger hydrogen bonding
and a more exothermic electrostatic interaction (Fromm
et al., 1995). It is possible that the higher afﬁnity provided by
arginine residues in a HS-binding interface could explain
why FGF18 has a lower stringency for HS sulfation than
other FGFs.
When secreted from mammalian cells, FGF18 acquires
4 kDa of N-linked oligosaccharide (Hu et al., 1998). FGF8b
subfamily members have an invariant potential glycosylation
site at Asn137, with FGF18 having a second site at Asn39. In
the FGF18 crystal structure, Asn137 is surface exposed and
would interact with Arg251 and Pro170 in FGFR2c if FGF18
is modelled according to the known FGF8b-FGFR2c com-
plex (Fig. 1C and S4A). Asn39 is not present in the structure,
but from the sequence-to-structure alignment (Fig. S4B)
would correspond to FGF8b Glu38. This residue faces away
from the FGFR2c interface and is unlikely to inﬂuence
binding. While it is possible that glycosylation at Asn137
could inﬂuence the ability of the FGF8 subfamily to bind
FGFRs, it has been reported that glycosylation is not critical
for FGF18 mitogenic activity on ﬁbroblast cell lines (Hu et al.,
1998). Other FGFs are glycosylated although its importance
to function remains to be fully elucidated.
A number of polymorphisms have been identiﬁed in
FGF18, including mutations in cancer patients (Table S2).
These polymorphisms were mapped to the structure of
FGF18 to analyze possible effects on protein interaction
interfaces or protein stability (Fig. 1C). Leu16Met is in the
N-terminal signal peptide and therefore does not have any
effect on the mature polypeptide. Arg49His is not in the
FGF18 crystal structure, but is structurally equivalent to
Arg49 in the FGF8b structure, which while adjacent to two
interacting residues the sidechain of Arg49 does not con-
tribute to the interface, and as such a mutation to histidine is
unlikely to alter the binding to FGFR. Arg112 and Lys145
may be located in the HS-binding interface based on their
interaction with sulfate ions and their mutation to histidine or
glutamine could have an effect of lowering afﬁnity for HS.
Arg166, although solvent-exposed, is outside the putative
HS- and FGFR-binding interfaces and a polymorphism here
is unlikely to have a large effect on FGF signaling. Phe153 is
solvent inaccessible and contributes to the hydrophobic core
of the protein. Leucine has a similar hydrophobicity and
therefore the mutation is unlikely to considerably destabilize
the protein.
In summary, we have solved the structure of the clinically
important FGF18 protein. The position of sulfate ions bound
to FGF18 provides insight into the putative HS-binding site
and allows comparison with the prototypical FGFs, FGF1,
and FGF2. The structure also reveals the molecular mech-
anism behind the speciﬁcity of FGF18 for FGFR c-isoforms
and the reduced afﬁnity for these compared to FGF8b. We
propose that based on the location of the Asn137 glycosyl-
ation site within the FGFR-binding interface, glycosylation of
FGF8 subfamily members could play a role in modulating
afﬁnity towards FGFRs.
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